US rare diseases specialist Soligenix (Nasdaq: SNGX) closed 19% lower after Tuesday’s trading following news of a setback with its lead drug candidate.
Soligenix earlier announced that the US Food and Drug Administration (FDA) had sent the company a Refusal to File letter for its HyBryte (synthetic hypericin) New Drug Application (NDA) in the treatment of early-stage cutaneous T-cell lymphoma (CTCL).
Upon preliminary review, the FDA determined that the NDA, submitted in December, was not sufficiently complete to permit substantive review.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze